Pharmaceuticals FDA Expands Approval of Sarepta Therapeutics’ Erevidys for Treatment of Duchenne Muscular Dystrophy Last updated: June 21, 2024 2:21 pm By bexib 0 Min Read Share SHARE Elevidys’ expanded scope of application includes Duchenne muscular dystrophy patients aged 4 years and older, regardless of ambulatory status. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article 30 Free SEO Tools: Boost Your Optimization Efforts (2024) Next Article Lawyer Explains What Ripple’s Latest Court Victory Means for XRP – Investorempires.com Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Moving towards retention: Planday reveals actionable insights to reduce hospitality staff turnover Hospitality & Tourism New CDC Respiratory Virus “Community Snapshot Caves to Covid Minimizers, Deceives Those Who Want to Stay Safe Economy My weekly reading for October 6, 2024 Economy Retail vacancy rate decreased slightly in the third quarter Economy